You are here
- Home
- Therapy Areas
- Oncology/Infection
Maintenance ZD1839 (IRESSA®) Following Completion of Front Line, Platinum-Based, Double Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (IMAC/Herbst)
- Disease
- lung cancer
- Drug Name
- IRESSA
- Generic Name
- gefitinib
- Sponsor
- AstraZeneca
- Drug Status
- Approved Medicine
- Phase
- III
- Start Date
- Jan 18, 1971
- Study Name
- Herbst trial
- Study Id
- D7913L00019
- ClinicalTrials.gov ID
- NCT00090675
- Recruiting Status
- Closed
- Protocol Status
- Not Available
- Report Status
- Not Available
